Trial Profile
Efficacy of Crizotinib in patients with advanced lung adenocarcinoma with ALK or ROS1 mutation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Oct 2018
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 10 Oct 2018 New trial record
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer